Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers

Oncotarget
Alessandra CiucciDaniela Gallo

Abstract

The notion that menopausal estrogen replacement therapy increases ovarian cancer risk, but only for the two more common types (i.e. serous and endometrioid), while possibly decreasing risk for clear cell tumors, is strongly suggestive of causality. However, whether estradiol (E2) is tumorigenic or promotes development of occult preexisting disease is unknown. The present study investigated molecular and cellular mechanisms by which E2 modulates the growth of high grade serous ovarian cancer (HGSOC). Results showed that ERα expression was necessary and sufficient to induce the growth of HGSOC cells in in vitro models. Conversely, in vivo experimental studies demonstrated that increasing the levels of circulating estrogens resulted in a significant growth acceleration of ERα-negative HGSOC xenografts, as well. Tumors from E2-treated mice had significantly higher proliferation rate, angiogenesis, and density of tumor-associated macrophage (TAM) compared to ovariectomized females. Accordingly, immunohistochemical analysis of ERα-negative tissue specimens from HGSOC patients showed a significantly greater TAM infiltration in premenopausal compared to postmenopausal women. This study describes novel insights into the impact of E2 on ...Continue Reading

References

Dec 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P B VermeulenL Y Dirix
Jun 24, 1998·Biochemical and Biophysical Research Communications·J T MooreT M Willson
Mar 24, 2000·Endocrine-related Cancer·S ChenC Yang
Aug 30, 2005·The American Journal of Pathology·Claire Lewis, Craig Murdoch
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ingo B Runnebaum, Ansgar Brüning
Dec 3, 2005·Nature Reviews. Immunology·Siamon Gordon, Philip R Taylor
Mar 24, 2006·Biochemical Pharmacology·Aurélie EscandePatrick Balaguer
Aug 30, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yuet-Kin LeungShuk-Mei Ho
Mar 3, 2007·Cancer Research·Piyush B GuptaCharlotte Kuperwasser
Oct 4, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Naim ShabaniIoannis Mylonas
Jan 22, 2008·The Journal of Steroid Biochemistry and Molecular Biology·Julia BollmannOliver Treeck
May 29, 2008·International Journal of Cancer. Journal International Du Cancer·Ivan ShaboJoar Svanvik
Jun 24, 2008·The Journal of Nutrition·Daniela GalloGiovanni Scambia
Jun 9, 2009·Gynecologic Oncology·Harriet O SmithEric R Prossnitz
Jun 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Trine O JensenTorben Steiniche
Jul 8, 2009·International Journal of Cancer. Journal International Du Cancer·Ivan ShaboJoar Svanvik
Sep 11, 2009·Journal of Leukocyte Biology·G SolinasP Allavena
Oct 13, 2009·Journal of Autoimmunity·Delisa Fairweather, Daniela Cihakova
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute
Sep 18, 2010·Cancer Chemotherapy and Pharmacology·Ilaria De StefanoDaniela Gallo
Jan 6, 2011·Pathology Oncology Research : POR·Agnieszka HalonPawel Surowiak
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Dec 20, 2011·Journal of Translational Medicine·Moniek Heusinkveld, Sjoerd H van der Burg
Mar 7, 2012·Current Pharmaceutical Design·Daniela GalloGabriella Ferrandina
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Prat
Nov 21, 2012·Journal of Ovarian Research·Satoe FujiwaraMasahide Ohmichi
Jan 2, 2013·Frontiers in Bioscience (Scholar Edition)·Nelly Auersperg
Jan 8, 2013·Technology in Cancer Research & Treatment·Chunyan LanJihong Liu
Feb 14, 2013·Steroids·Fiona SimpkinsJoyce Slingerland
May 10, 2013·Seminars in Immunopathology·Subhra K BiswasAlberto Mantovani
Jun 15, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Alberto Mantovani, Massimo Locati
Jul 11, 2013·Nature Communications·Silvia DomckeNikolaus Schultz
Feb 18, 2014·Molecular and Cellular Endocrinology·Eric R Prossnitz, Matthias Barton
Feb 26, 2014·The Journal of Steroid Biochemistry and Molecular Biology·Jennifer R Ribeiro, Richard N Freiman
Apr 29, 2014·The Journal of Investigative Dermatology·Laura CampbellMatthew J Hardman

❮ Previous
Next ❯

Citations

Feb 22, 2018·International Journal of Molecular Sciences·Natalie J RothenbergerLaura P Stabile
May 22, 2018·International Journal of Genomics·Jiaxing HeTianmin Xu
Feb 12, 2021·Cellular Signalling·MelissaR PitmanStuart M Pitson
Feb 19, 2021·Molecular and Cellular Biochemistry·Deborah MolehinKevin Pruitt
Oct 13, 2021·The Journal of Clinical Investigation·Binita ChakrabortyDonald P McDonnell

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
electrophoresis
PCR

Software Mentioned

Quantity One
Rad
GraphPad
Bio
GraphPad Prism

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.